» Articles » PMID: 39544245

Mouse Models for the Study of Liver Fibrosis Regression and

Overview
Specialty Gastroenterology
Date 2024 Nov 15
PMID 39544245
Authors
Affiliations
Soon will be listed here.
Abstract

This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression, a pivotal process in preventing the progression of metabolic dysfunction-associated steatohepatitis to irreversible liver cirrhosis. These models provide a valuable resource for understanding the cellular and molecular processes underlying fibrosis regression in different contexts. The primary focus of this review is on the most commonly used models with diet- or hepatotoxin-induced fibrosis, but it also touches upon genetic models and mouse models with biliary atresia or parasite-induced fibrosis. In addition to emphasizing models, we briefly summarized current approaches designed for studying fibrosis regression and provided an outlook on evolving methodologies that aim to refine and reduce the number of experimental animals needed for these studies. Together, these models contribute significantly to unraveling the underlying mechanisms of liver fibrosis regression and offer insights into potential therapeutic interventions. By presenting a comprehensive overview of these models and highlighting their respective advantages and limitations, this review serves as a roadmap for future research.

References
1.
Leite S, Roosens T, El Taghdouini A, Mannaerts I, Smout A, Najimi M . Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. Biomaterials. 2015; 78:1-10. DOI: 10.1016/j.biomaterials.2015.11.026. View

2.
Lee Y, Seki E . In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations. Cell Mol Gastroenterol Hepatol. 2023; 16(3):355-367. PMC: 10444957. DOI: 10.1016/j.jcmgh.2023.05.010. View

3.
Westra I, Pham B, Groothuis G, Olinga P . Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica. 2012; 43(1):98-112. DOI: 10.3109/00498254.2012.723151. View

4.
Younis M, Sato Y, Elewa Y, Harashima H . Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice. J Control Release. 2023; 361:592-603. DOI: 10.1016/j.jconrel.2023.08.021. View

5.
Traber P, Zomer E . Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013; 8(12):e83481. PMC: 3867460. DOI: 10.1371/journal.pone.0083481. View